Marlborough's Ocata awarded 2 patents
Marlborough’s Ocata Therapeutics (formerly Advanced Cell Technology), said it has been awarded two new U.S. patents for its cell therapy technology to treat ophthalmic, autoimmune and inflammatory diseases.
The patents are directed to Ocata’s Hemangio-derived Mesenchymal Cells (HMCs), which the company said introduces a “new era” of treatment for patients with such conditions.
“HMCs have the potential to deliver greater therapeutic results than (traditional therapies) that have been the focus of clinical development for the past decade. Importantly, this technology could enable scalable manufacturing for global distribution of potent HMCs for off-the-shelf therapeutic use,” Dr. Robert Lanza, chief scientific officer at Ocata and co-inventor on the patents, said in a statement.
A clinical-stage company focused on developing regenerative ophthalmology therapeutics, Ocata is a leader in the field of stem cell treatment. Its most advanced products are in clinical trial for the treatment of Stargardt’s macular degeneration, as well as age-related and myopic macular degeneration.
WBJ Web Partners
Most Recent
Most Recent
0 Comments